GGFG-Eribulin（Compound GGFG）是一种用于合成ADCs的ADC-药物连接子偶联物。它由ADC细胞毒素Exatecan和连接子构成，以实现靶向输送药物。

Val-Cit-amide-Cbz-N(Me)-Maytansine是一种可用于构建抗体和双特异性抗原结合分子，能够特异性结合肝细胞生长因子受体c-Met (MET)以及用于制备抗体药物偶联物(antibody-drug conjugates) (ADCs)的化合物。

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2. MMAE, a potent tubulin inhibitor, serves as the cytotoxic component in this formulation.

Sulfo-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs) that employs the maytansine-based payload (DM4, an antitubulin agent) connected through the sulfo-SPDB linker.

MC-Val-Cit-PAB-duocarmycin is an antibody-drug conjugate (ADC) linker that combines duocarmycin, a potent DNA minor groove-binding alkylating agent, with an antitumor drug through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.

NAMPT inhibitor-linker 1, a drug-linker conjugate for ADC, integrates an NAMPT inhibitor (as a payload) with a linker. In the formulation of ADC-3, it pairs with an anti-c-Kit monoclonal antibody, demonstrating strong efficacy against c-Kit expressing cell lines, specifically GIST-T1 and NCI-H526, where it exhibits IC50 values of <3 pM and 9 pM, respectively.

Deruxtecananalog 2（示例9 P3）是一种含活性分子-linker的Deruxtecan类似物，由Camptothecin（一种对多种癌症如结直肠癌、乳腺癌、肺癌和卵巢癌具有抗肿瘤活性的Topo I抑制剂）和linker组成，主要用于开发针对EGFR2的抗体药物偶联物（ADC）活性分子。

SG3199-Val-Ala-PAB为Tesirine合成中间体，该物质作为用于抗体偶联活性分子(ADC)的活性分子-linker连接物，适用于多种癌症研究。

PB038为一种ADC药物，由可降解的PEG linker及毒素分子依喜替康(Exatecan)构成的偶联物。